MAPT and Alzheimer disease: Recent work suggested high clinical value of plasma biomarkers, such as Aβ40, Aβ42, phosphorylated tau isoforms (pTau181, pTau217), NfL, and GFAP, in diagnosing and staging AD and other neurodegenerative conditions.4